Navigation Links
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Date:9/2/2010

>  

STOCKHOLM, September 2, 2010 /PRNewswire/ --

- Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups (diabetes, acute coronary syndrome and multiple lesion). These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at 9 months follow-up and on clinical outcomes at 18 month follow up of the randomized comparison of the CYPHER(R) Stent and the Endeavor(R) Stent.

The initial results of the SORT OUT III study were published in the Lancet and showed significantly reduced adverse events at 9 and 18 months for the CYPHER(R) Sirolimus-eluting Coronary Stent over Medtronic's Endeavor(R) Stent in an unselected group of 2,332 patients undergoing coronary intervention in real world clinical practice. The authors reported that subgroup analysis of the primary endpoint of 9-month Major Adverse Cardiac Events (MACE, defined as a composite of cardiac death, myocardial infarction [MI], or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes, and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at 9 months
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
2. Resverlogix Scientific Data Presented at EAS Congress
3. Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
4. Delcath Highlights Phase III Trial Results Presented at ASCO
5. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
6. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
7. Two-Year Follow up Data of NuBacĀ® IDE Feasibility Study Was Presented at SAS Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
9. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
10. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
11. Gramene Announces Scholarships for Groups Underrepresented in Science to Learn How to Use Bioinformatics and Genomics Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... will provide new insights on mechanics of fecal microbiota transplantation in C. difficile ... study the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment ...
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., ... announced in a paper published this week in the scientific journal Viruses ( ... diagnostic techniques currently used to detect the Ebola virus. Noblis worked with the ...
(Date:6/30/2015)... ... ... Matrix Marketing Group, LLC , a leading provider of performance-based marketing ... its account management department as vice president of client services. Amanda Gregory joins ... and delivery expertise to the growing Matrix Marketing Group team in Denver, Colorado. ...
(Date:6/30/2015)... N.Y. , June 30, 2015  Custom Computer ... announced today that they are silver sponsors of the ... official PCDC sponsor, Custom is lending their support of ... low-income communities. Since its founding in 1993, ... the primary care area.  PCDC has financed over 100 ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Matrix Marketing Group Expands Client Services Team 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2
... , WAYNE, N.J., Sept. 24 ... of Surgery and Director of Coronary Surgery and Advanced Coronary ... has completed the world,s first use of the MAQUET Minimized ... endoscopic heart surgery. The new cardiopulmonary bypass technology is the ...
... , SALT LAKE CITY, Sept. ... through the development of molecular diagnostics, announced today that its ... spine specialists in the United States. SCOLISCORE is a saliva-based ... scoliosis, an abnormal lateral curvature of the spine. Spine surgeons ...
... /PRNewswire-Asia-FirstCall/ --, -- Q4 FY 2009 Revenues increased 43.2% to ... $2.2 Million with diluted EPS of $0.08, -- FY 2009 ... Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS of ... to $8.3 Million, -- June 30, 2009 Cash and equivalents ...
Cached Biology Technology:MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 2Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... and Harvard Medical School have shown how a key ... triggering other changes that allow the AIDS virus to ... Feb. 24 issue of the journal Nature, offer clues ... Researchers led by Howard Hughes Medical Institute Investigator Stephen ...
... human embryonic,stem cells have been contaminated with a ... human subjects,according to research by investigators at the ... and the Salk Institute in La Jolla,California.,In a ... journal Nature,Medicine, the researchers found that human embryonic ...
... available. However, a,similar and equally dangerous addiction, alcoholism, ... be? Researchers from the University of,California in San ... addiction in rodents. We can only hope that ... close future; it would help fix a,problem that ...
Cached Biology News:Elusive HIV shape change revealed; Key clue to how virus infects cells 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4Controversial drug shown to act on brain protein to cut alcohol use 2Controversial drug shown to act on brain protein to cut alcohol use 3
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
... process and you reduce the chance of ... CEQ 8000. Developed using Beckman Coulters extensive ... capillary electrophoresis technology, the CEQ 8000 is ... system automatically fills the capillary array with ...
... standard electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 13 ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
Biology Products: